根据《中华人民共和国药品管理法》《药品生产监督管理办法》《药品检查管理办法（试行）》《药品生产质量管理规范符合性检查工作程序》有关规定及 要求，我局对华东医药（西安）博华制药有限公司等7家药品生产企业进行药品生产质量管理规范符合性检查和审核，经现场检查并综合评定，现将检查结 果通告如下： | 受托方： 榆林利君 制药有限 | | | | | | --- | --- | --- | --- | --- | | 公司 | | | | | | 西安力邦 | 西安市未央 | | 2025年9 月16 | | | 制药有限 | 区六村堡工 | 原料药：右泛醇（二车间、三车间、净化二车间，右泛醇生产线） | 日-2025 | 符 | | 公司 | 业园丰产路 42号 | | 年9月19 | 合 | | | | | 日 | | | 西安力邦 | 西安市高新 | | 2025年9 月22 | | | 制药有限 | 区科技一路 | 前列地尔注射液（一车间，2线）、小容量注射剂（一车间，1线、2线） | 日-2025 | 符 | | 公司 | 22号 | | 年9月24 | 合 | | | | | 日 | | | | 辽宁省新民 ...

Group 1 - Xinpeng Co., Ltd. provided a guarantee of 50 million yuan for its wholly-owned subsidiary, increasing the total guarantee amount to 1.258 billion yuan, which is 115.47% of the latest audited net assets [1] - Yonggui Electric's subsidiary signed a contract worth 15.8652 million yuan with CRRC Zhuzhou for supplying components for the Wuhan rail transit project [1] - Huada Technology secured project designations from multiple domestic automakers and battery companies, with a total expected sales amount of 2.9 billion yuan, over 80% of which is related to new energy projects [2] Group 2 - China National Machinery International signed a contract for a 5.71 billion yuan hospital construction project in Iraq, which represents 4.68% of the company's expected revenue for 2024 [3] - Fangzhi Technology plans to acquire 100% of Zhixiang Technology for 116 million yuan, focusing on AI-driven smart learning and sports solutions [4] - Demingli is in the early stages of planning a refinancing initiative, with no specific details on the amount or method yet [5] Group 3 - Hesheng Silicon Industry announced a shareholder's plan to reduce holdings by up to 2.29%, equating to 27.0706 million shares [7] - ST Lanhua's subsidiary plans to invest up to 65 million yuan in a juice beverage project in Chongqing [8] - Ruizhi Pharmaceutical developed an automated synthesis system for antibody-drug conjugates and nucleoside monomers in collaboration with East China Normal University [9] Group 4 - Lianying Laser's controlling shareholder intends to reduce holdings by up to 3 million shares, representing 0.88% of the total share capital [10] - Songyuan Safety's controlling shareholder plans to reduce holdings by up to 1% of the total share capital [12] - ST Kaixin's actual controller and major shareholders plan to transfer 5% of the company's shares at a price of 27.85 yuan per share [13] Group 5 - Bojun Technology plans to invest approximately 1 billion yuan in a new automotive parts production base, aiming for an annual capacity of 24 million sets [13] - Litong Electronics' controlling shareholder committed to not reducing holdings for 24 months, while other shareholders plan to reduce a total of 3.03% of shares [14] - Yaoyigou's actual controller intends to transfer 5.23% of shares to a company director at a price of 24 yuan per share [15] Group 6 - Baiwei Storage submitted H-share listing application materials to the China Securities Regulatory Commission [18] - Jinshi Yaya obtained a drug registration certificate for glucosamine sulfate capsules, which are suitable for osteoarthritis treatment [19] - Shangtai Technology plans to invest approximately 4.07 billion yuan in a lithium-ion battery anode material project [19] Group 7 - Xinlitai's shareholder plans to reduce holdings by up to 800,000 shares, representing 0.07% of the total share capital [20] - Yunnan Baiyao elected Zhang Wenxue as the chairman of the board for a three-year term [21] - Huading Co., Ltd. announced that two shareholders plan to reduce their holdings by up to 3% of the total share capital [23] Group 8 - Jiahua Technology's shareholder plans to reduce holdings by up to 0.65% of the total share capital [25]

Group 1: Company Announcements - ChaoYing Electronics' wholly-owned subsidiary plans to invest 1.468 billion RMB in an AI computing high-end printed circuit board expansion project in Thailand, aiming to enhance its product layout in high-end PCB applications such as routers and AI servers [1] - DeMingLi is in the process of planning a refinancing matter, which is still in the internal communication stage without a clear plan or determined financing amount [1] - *ST YuanCheng's stock has triggered mandatory delisting due to a market capitalization below 500 million RMB for 20 consecutive trading days, leading to a suspension of trading starting November 11, 2025 [1] Group 2: Investment and Cooperation - ZhongBei Communication signed a framework agreement for comprehensive computing services worth 1 billion RMB with Hongxin Electronics, with a service period of 60 months [2] - ShangTai Technology plans to invest approximately 4.07 billion RMB in a project to produce 200,000 tons of lithium-ion battery anode materials in Shanxi Province [3] Group 3: Clinical Trials and Approvals - Maiwei Bio's innovative drug 9MW3811 injection for pathological scars has received approval for a Phase II clinical trial, with plans to start by the end of 2025, positioning it as the first IL-11 targeted drug in this indication [3]

Core Viewpoint - The company has received approval for its glucosamine sulfate capsule from the National Medical Products Administration, which is considered equivalent to passing the consistency evaluation [2]. Group 1 - The company, Sichuan Jinshi Asia Pharmaceutical Co., Ltd., announced that its wholly-owned subsidiary, Zhejiang Yake Pharmaceutical Co., Ltd., has been granted a drug registration certificate for glucosamine sulfate capsules [2].

Core Viewpoint - Kingstone Pharmaceuticals (300434.SZ) announced that its wholly-owned subsidiary, Zhejiang Yake Pharmaceutical Co., Ltd., has received the drug registration certificate for Glucosamine Sulfate Capsules from the National Medical Products Administration, which is considered equivalent to passing the consistency evaluation [1] Group 1 - The approved product, Glucosamine Sulfate Capsules, is a non-prescription analgesic drug [1] - The indications for Glucosamine Sulfate Capsules include primary and secondary osteoarthritis [1]

Core Viewpoint - Company Jinshi Yao (300434.SZ) has received approval from the National Medical Products Administration for its subsidiary Zhejiang Yake Pharmaceutical Co., Ltd. to market Glucosamine Sulfate Capsules, which are classified as non-prescription analgesics for osteoarthritis treatment [1] Group 1: Product Approval - The approval includes the issuance of a Drug Registration Certificate for Glucosamine Sulfate Capsules, which is considered equivalent to passing the consistency evaluation [1] - Glucosamine is a natural amino monosaccharide that serves as a precursor for the synthesis of proteoglycans, enhancing the repair capacity of chondrocytes [1] Group 2: Product Functionality - The capsules are indicated for primary and secondary osteoarthritis, helping to alleviate joint pain and improve joint function [1] - Glucosamine can inhibit enzymes that damage cartilage, such as collagenase and phospholipase A2, and prevent the production of superoxide free radicals that harm cells [1] - The product promotes the repair and reconstruction of cartilage matrix, potentially delaying the pathological process of osteoarthritis and improving patient outcomes [1]

Core Viewpoint - The company Jinshi Yiyao (300434.SZ) announced that its wholly-owned subsidiary, Zhejiang Yake Pharmaceutical Co., Ltd., has received the drug registration certificate for Glucosamine Sulfate Capsules from the National Medical Products Administration, which is considered equivalent to passing the consistency evaluation [1] Group 1: Product Information - Glucosamine Sulfate Capsules are classified as non-prescription analgesic drugs, indicated for primary and secondary osteoarthritis [1] - Glucosamine is a natural amino monosaccharide that serves as a precursor for the synthesis of proteoglycans, stimulating chondrocytes to produce proteoglycans with normal polymer structures [1] - The product enhances the repair capacity of chondrocytes, inhibits damaging enzymes such as collagenase and phospholipase A2, and prevents the production of superoxide free radicals in damaged cells, promoting the repair and reconstruction of cartilage matrix [1] Group 2: Therapeutic Benefits - The capsules can delay the pathological process of osteoarthritis pain and the progression of the disease, improve joint mobility, and alleviate pain [1]

Group 1 - The core point of the article is that Jinshi Yiyao has received approval for its glucosamine sulfate capsule from the National Medical Products Administration, which is considered equivalent to passing the consistency evaluation [1] - Jinshi Yiyao's revenue composition for the first half of 2025 is as follows: 82.76% from the pharmaceutical manufacturing industry, 14.09% from the machinery manufacturing industry, and 3.16% from real estate leasing and management [1] - As of the report date, Jinshi Yiyao has a market capitalization of 4.8 billion yuan [1]

Core Viewpoint - The company, Kingstone Pharmaceuticals, announced that its wholly-owned subsidiary, Zhejiang Yake Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the registration certificate of Glucosamine Sulfate Capsules, which is considered equivalent to passing the consistency evaluation [1] Group 1 - The approved product, Glucosamine Sulfate Capsules, is a non-prescription analgesic medication [1] - The indications for Glucosamine Sulfate Capsules include primary and secondary osteoarthritis [1]

Core Viewpoint - The company has received approval for its glucosamine sulfate capsules, which are indicated for osteoarthritis, marking a significant milestone in its product development and market entry strategy [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Zhejiang Yake Pharmaceutical Co., Ltd., has been granted a drug registration certificate for glucosamine sulfate capsules by the National Medical Products Administration (NMPA) [1] - The approval is considered equivalent to passing the consistency evaluation for generic drugs, enhancing the company's competitive position in the market [1] Group 2: Product Information - Glucosamine sulfate capsules are classified as non-prescription analgesic medications, specifically indicated for primary and secondary osteoarthritis [1] - The application for this product was submitted to the NMPA in May 2024 and has since been accepted [1] Group 3: Market Context - As of the announcement date, over twenty manufacturers, including the company, have either passed or are deemed to have passed the consistency evaluation for glucosamine sulfate capsules [1]